logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Illumina Acquired Fluent BioSciences to Accelerate Single-Cell Analysis and Discovery to a Broader Customer Base

Illumina Inc The latest take over by Illumina, Inc. ( ILMN ) has been a company with advanced technology known as Fluent BioSciences , a developer of emerging and highly differentiated single-cell technology.   From Illumina Inc Informing the biotech...

Read More

July 10, 2024

0

Gilead Sciences Stock Rallies Following Improving Survival of Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences Good News for Breast Cancer Gilead Sciences' ( GILD )  product Trodelvy® has significantly improved the Overall Survival ( OS ) in Pre-Treated HR+/HER2- metastatic breast cancer patients in the TROPiCS-02 study. Today, Gilead Sciences' ( GILD )...

Read More

August 15, 2022

0

Lexeo Therapeutics Announces Positive Data of lx2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics in the NEWS On July 15, 2024, Lexeo Therapeutics ( LXEO ) announced positive interim data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Across both the Lexeo SUNRISE-FA Phase 1/2 clinical trial ( NCT05445323 )...

Read More

July 16, 2024

0

IVERIC Bio: Undeniable Promising News Today

IVERIC Bio ~ September 6, 2022 IVERIC bio ( ISEE ) announced positive results from GATHER2 second Phase 3 clinical trial of Zimura® (avacincaptad pegol) - a novel investigational complement C5 inhibitor for the treatment of geographic atrophy ( GA...

Read More

September 6, 2022

0

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for ALS

Amylyx Pharmaceuticals in the News Amylyx Pharmaceuticals ( AMLX ) : The U.S. FDA Peripheral and Central Nervous System Drugs Advisory Committee has voted (7 yes votes and 2 no votes) that the available evidence of effectiveness is sufficient to support approval of AMX0035...

Read More

September 8, 2022

0

Akero Therapeutics: Efruxifermin Met Primary Endpoint for Both Dose Groups in NASH Patients

Akero Therapeutics Akero Therapeutics ( AKRO ) - a clinical-stage company, today released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin ( EFX ) in patients with pre-cirrhotic...

Read More

September 13, 2022

0

Akero Therapeutics Reports Q2 2024 Financial Results and Business Update

Akero Therapeutics Q2 and Business Update Akero Therapeutics ( AKRO ) reported second-quarter financial results for the period ending June 30, 2024,  and provided business updates. From Akero Therapeutics Andrew Cheng, president and CEO said, “The second quarter of 2024...

Read More

August 9, 2024

0

Intellia Therapeutics: Excellent News from NTLA-2001 Phase 1 Clinical Trial

Intellia Therapeutics  Intellia Therapeutics.( NTLA ) and  Regeneron Pharmaceuticals ( REGN ) today announced positive interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (...

Read More

September 16, 2022

0

From Biogen and Eisai: Lecanemab Confirmatory Phase 3 Clarity Met Primary Endpoint for Early Alzheimer’s Disease  

Biogen & Eisai Co and Early Alzheimer's Disease  From Tokyo and Cambridge, Eisai Co., Ltd. and Biogen Inc. ( BIIB ) announced positive topline results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab. The product...

Read More

September 28, 2022

0

Gilead Sciences Livdelzi Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences Approval Gilead Sciences ( GILD ) today announced that the U.S. FDA has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis ( PBC ) in combination with ursodeoxycholic acid ( UDCA ) in adults...

Read More

August 15, 2024

0

  • Previous
  • 1
  • 2
  • ...
  • 161
  • 162
  • 163
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy